GENE ONLINE|News &
Opinion
Blog

2021-11-25| Special

Cancer Cells Build Nano-Highways to Hijack Mitochondria from Immune Cells

by Sahana Shankar
Share To
Cancer cells escape identification and neutralization by the immune system by multiple strategies. One of them is ligand-mediated deactivation of immune checkpoints, which spurred the advent of cancer immunotherapy with anti-PD1.

However, not all patients respond well to immunotherapy, suggesting other immune evasion pathways in cancers. Researchers from MIT and Brigham and Women’s Hospital employed nanotechnology to unravel a novel mechanism of cancer cells to attack and suppress immune cells.

Co-culture of breast cancer cells with effector T cells and subsequent high-resolution imaging showed a physical linkage between cancer cells and nearby T cells with an average width of 100-1000nm. These nanotubes were composed of actin and other cytoskeletal proteins, suggesting that they may be involved in intercellular transport.

GO Prime with only $1.49 now

LATEST
Major U.S. Organization BIO Severs Ties With Member WuXi AppTec Amid U.S. Government’s Security Concerns
2024-03-15
Mayo Clinic Researchers Invent Hypothesis-Driven AI for Cancer Research Breakthroughs
2024-03-14
Chinese Biotechs Seeks IPO Growth on US Shores
2024-03-13
Pearl Bio Enters $1 Billion Partnership Agreement with MSD for Biologic Therapies
2024-03-13
German Study Links PFAS Exposure to Adverse Lipid Profiles and Cardiovascular Risk
2024-03-13
Global Pharmaceutical Investment in Asia: A Strategic Focus Amidst Evolving Market Dynamics
2024-03-12
Taiwanese Hospitals Make Strong Showing in “World’s Best Hospitals” Ranking
2024-03-12
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top